Showing 2391-2400 of 4066 results for "".
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Studyhttps://reachmd.com/news/mira-pharmaceuticals-achieves-100-reversal-of-neuropathic-pain-with-oral-ketamir-2-in-breakthrough-study/2468049/Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pha
- Systemic Thrombolysis of Acute Portal Venous System Thrombosis in Patients with Liver Cirrhosis: A Pilot Studyhttps://reachmd.com/news/systemic-thrombolysis-of-acute-portal-venous-system-thrombosis-in-patients-with-liver-cirrhosis-a-pilot-study/2463187/The prevalence of Portal Vein Thrombosis (PVT) varies significantly at different stages of liver disease: 10% in compensated patients, 17% in decompensated patients, 9% in those with acute decompensated cirrhosis, and 2-26% in post-liver transpl
- More Than 1 Billion People Around the Globe Are Facing Obesityhttps://reachmd.com/news/more-than-1-billion-people-around-the-globe-are-facing-obesity/2462507/March 26, 2024 · Baton Rouge, LA Pennington Biomedical’s Dr. Peter Katzmarzyk was among hundreds of researchers who tracked BMI measurements gathered from more
- Chlorogenic Acid Shields Against Bone Loss, Boosts Osteoblastshttps://reachmd.com/news/chlorogenic-acid-shields-against-bone-loss-boosts-osteoblasts/2462465/"[...] chlorogenic acid appears to be a promising candidate for the management of osteoporosis."BUFFALO, NY- March 26, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" a
- New Clinical Practice Guideline Provides Evidence-Based Recommendations for Immunotherapy for Inhalant Allergyhttps://reachmd.com/news/new-clinical-practice-guideline-provides-evidence-based-recommendations-for-immunotherapy-for-inhalant-allergy/2457330/Embargoed for Release: February 26, 2024, 2:00 pm (ET) Newswise — ALEXANDRIA, VA —The American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) published the Clinical Practice Guideline: Immunotherapy for Inhalant Alle
- Gene Editing in Agriculture: BTI Scientist Advocates for CRISPR Innovations to Senate Committeehttps://reachmd.com/news/gene-editing-in-agriculture-bti-scientist-advocates-for-crispr-innovations-to-senate-committee/2462926/Georg Jander addressing an audience in the offices of the U.S. Senate Committee on Agriculture, Nutrition, and Forestry On April 23rd, Georg Jander, a professor fro
- Next-Generation CRISPR-Based Gene-Editing Therapies Tested in Clinical Trialshttps://reachmd.com/news/next-generation-crispr-based-gene-editing-therapies-tested-in-clinical-trials/2467739/Going from the laboratory to an approved therapy in 11 years is no mean feat. That is the story of the world’s first approved CRISPR–Cas9 therapy,
- A Nanotechnology‐Based CRISPR/Cas9 Delivery System for Genome Editing in Cancer Treatmenthttps://reachmd.com/news/a-nanotechnologybased-crisprcas9-delivery-system-for-genome-editing-in-cancer-treatment/2457036/by Sichuan International Medical Exchange and Promotion Association Schematic of the CRISPR/Cas9 system and its nanotechnology delivery method
- Evaluating Lenacapavir and bNAbs in HIV-1https://reachmd.com/news/lenacapavir-bnabs-hiv-1/2487075/Key Takeaways Week-26 virologic control was broadly similar between a long-acting regimen and continued oral ART in this phase 2 comparison. Adverse-event rates were broadly comparable after excluding injection-site reactions, and no serious adverse ev
- Early and Sustained Depemokimab Efficacy in Type 2 Asthmahttps://reachmd.com/news/early-and-sustained-depemokimab-efficacy-in-type-2-asthma/2486867/Key Takeaways Depemokimab was associated with fewer first exacerbations than placebo over 52 weeks, and benefit appeared by week 4. Improvements were reported across each 26-week dosing period in symptom and quality-of-life measures, with sustained res